Science Corporation’s PRIMA Chip First Implanted in Stargardt Patient
Current overview (not historical)
Science Corporation’s CEO Max Hodak announced that the company has implanted its PRIMA retinal chip in the first patient with Stargardt disease. During the initial postoperative recovery session, the patient was able to see letters, and in a subsequent session could read words. The surgery took place in May 2026 at Sydney Eye Hospital as part of an ongoing clinical trial. Science Corporation describes the device as delivering a central‑field, high‑contrast, black‑and‑white patch rather than a full‑field color vision. The chip provides a small, sharply defined area of vision, allowing the patient to perceive a few letters at a time. This milestone marks the first human use of the PRIMA system for Stargardt disease, a rare retinal degenerative condition. While the early results are promising, the company notes that the technology does not restore wide‑field color vision and that further trials are needed to assess long‑term efficacy and safety.
Written with AI from the reporting · updated 10/14/2026
Expand the detailed fact route and sources
Story route
A station-by-station route from the first public evidence onward; every station carries its own evidence and uncertainty.
- 1Unclassified fact stationMay 1, 00:00recorded Oct 14, 22:23single sourcerevised
Science Corporation implants PRIMA chip in first Stargardt d
Read original source ↗ TechCrunch · AIReplay this moment in the explorerEvidence & revisions · 1 source records
- Subject：
- science-corporation
- Action：
- implanted PRIMA chip
- Object：
- first Stargardt disease patient
- Occurred (fact side)：
- May 1, 00:00
- Published (valid side)：
- Oct 14, 07:13
- First seen (known side)：
- Oct 14, 22:23
Fact stationSingle source · one-sided claimRevisedCopy may have been revised later; time replay is bounded. Layer labels group reading only, not causation between layers.
Uncertainty marks flag where to check the sources; they are not proven causation.
Report timeline
Explore every side through dated source reports.
- TechCrunch · AIRelated fact: single sourceSource report revisedScience Corporation Implants Vision-Restoring Chip PRIMA in First Stargardt Disease Patient
Report first recorded Oct 14, 22:23
Science Corporation CEO Max Hodak announced that the company implanted its vision-restoring chip, PRIMA, into its first patient with Stargardt disease, an inherited eye disease affecting approximately 150,000 people worldwide. The patient saw a letter during the first rehabilitation session and read a word during the second. PRIMA is commercially available in Europe for geographic atrophy, an advanced form of age-related macular degeneration, and the implant, a two by two millimeter device, functions as artificial photoreceptors, transmitting a view via camera-equipped glasses to restore sharp, high-contrast, black and white central vision, though the field of view is currently limited.
Read original source ↗
Event discussion
Reader opinions are hosted on GitHub Discussions; posting requires a GitHub account. Comments are not verified facts.